Virax Biolabs (VRAX) Common Equity (2021 - 2023)

Virax Biolabs (VRAX) has 3 years of Common Equity data on record, last reported at $8.9 million in Q1 2023.

  • For Q1 2023, Common Equity rose 844.04% year-over-year to $8.9 million; the TTM value through Mar 2023 reached $8.9 million, up 844.04%, while the annual FY2023 figure was $8.9 million, 844.04% up from the prior year.
  • Common Equity reached $8.9 million in Q1 2023 per VRAX's latest filing, up from -$1.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $8.9 million in Q1 2023 and bottomed at -$1.2 million in Q1 2022.
  • Average Common Equity over 3 years is $2.3 million, with a median of -$831814.0 recorded in 2021.
  • Peak YoY movement for Common Equity: crashed 43.87% in 2022, then surged 844.04% in 2023.
  • A 3-year view of Common Equity shows it stood at -$831814.0 in 2021, then plummeted by 43.87% to -$1.2 million in 2022, then soared by 844.04% to $8.9 million in 2023.
  • Per Business Quant database, its latest 3 readings for Common Equity were $8.9 million in Q1 2023, -$1.2 million in Q1 2022, and -$831814.0 in Q1 2021.